📊 ALLR Key Takeaways
Is Allarity Therapeutics, Inc. (ALLR) a Good Investment?
Allarity Therapeutics is a pre-revenue pharmaceutical company with substantial operating losses and negative cash flow, burning approximately $11.6M annually with only $16.9M in cash reserves. The company faces critical existential risk as it will deplete its cash runway within 18 months at current burn rates, with no clear path to profitability or positive cash generation.
Allarity Therapeutics' fundamentals remain very weak: the company is generating negative revenue, deeply negative operating income, and substantial free cash outflows, which indicates the business is still far from a sustainable operating model. While the balance sheet is currently supported by a solid cash position and modest leverage, the ongoing cash burn materially outweighs those strengths and raises meaningful financing risk if commercialization or partnership progress does not improve.
Why Buy Allarity Therapeutics, Inc. Stock? ALLR Key Strengths
- Strong liquidity position with $16.9M in cash and 2.33x current ratio providing near-term operational runway
- Conservative leverage with 0.22x debt-to-equity ratio limiting financial distress risk
- Pharmaceutical sector offers high-growth potential if development programs achieve clinical success
- Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio
- Low balance-sheet leverage with debt-to-equity of 0.22x
- Net loss and diluted EPS improved year over year, indicating some loss compression
ALLR Stock Risks: Allarity Therapeutics, Inc. Investment Risks
- Severe cash burn of $11.9M annual free cash flow will exhaust reserves within approximately 18 months without revenue generation or additional financing
- Negative revenue of $1.3M indicates cost structure issues and no commercial traction despite sector presence
- Operating losses of $9.7M and net losses of $7.9M with deteriorating financial position typical of failed clinical-stage biotech programs
- Negative revenue and severely negative margins point to very poor underlying business quality
- Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement
- Negative ROE, negative ROA, and deeply negative interest coverage show weak profitability and limited financial resilience
Key Metrics to Watch
- Cash runway depletion timeline and need for dilutive financing
- Revenue trajectory and timing of first commercial product approval
- Monthly operating cash burn rate and runway extension initiatives
- Quarterly operating cash burn relative to cash on hand
- Revenue normalization and operating loss trend
Allarity Therapeutics, Inc. (ALLR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 881.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.33x current ratio provides a solid financial cushion.
ALLR Profit Margin, ROE & Profitability Analysis
ALLR vs Healthcare Sector: How Allarity Therapeutics, Inc. Compares
How Allarity Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allarity Therapeutics, Inc. Stock Overvalued? ALLR Valuation Analysis 2026
Based on fundamental analysis, Allarity Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allarity Therapeutics, Inc. Balance Sheet: ALLR Debt, Cash & Liquidity
ALLR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allarity Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3,093.42 indicates the company is currently unprofitable.
ALLR Revenue Growth, EPS Growth & YoY Performance
Allarity Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALLR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allarity Therapeutics, Inc. (CIK: 0001860657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALLR
What is the AI rating for ALLR?
Allarity Therapeutics, Inc. (ALLR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALLR's key strengths?
Claude: Strong liquidity position with $16.9M in cash and 2.33x current ratio providing near-term operational runway. Conservative leverage with 0.22x debt-to-equity ratio limiting financial distress risk. ChatGPT: Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio. Low balance-sheet leverage with debt-to-equity of 0.22x.
What are the risks of investing in ALLR?
Claude: Severe cash burn of $11.9M annual free cash flow will exhaust reserves within approximately 18 months without revenue generation or additional financing. Negative revenue of $1.3M indicates cost structure issues and no commercial traction despite sector presence. ChatGPT: Negative revenue and severely negative margins point to very poor underlying business quality. Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement.
What is ALLR's revenue and growth?
Allarity Therapeutics, Inc. reported revenue of $-1.3M.
Does ALLR pay dividends?
Allarity Therapeutics, Inc. pays dividends, with $0.3M distributed to shareholders in the trailing twelve months.
Where can I find ALLR SEC filings?
Official SEC filings for Allarity Therapeutics, Inc. (CIK: 0001860657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALLR's EPS?
Allarity Therapeutics, Inc. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALLR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Allarity Therapeutics, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALLR stock overvalued or undervalued?
Valuation metrics for ALLR: ROE of -65.4% (sector avg: 15%), net margin of 583.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALLR stock in 2026?
Our dual AI analysis gives Allarity Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ALLR's free cash flow?
Allarity Therapeutics, Inc.'s operating cash flow is $-11.6M, with capital expenditures of $298.0K. FCF margin is 881.6%.
How does ALLR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 583.4% (avg: 12%), ROE -65.4% (avg: 15%), current ratio 2.33 (avg: 2).